ChroMedX!
Eventuell schon Insider die von baldigen News (Vertragsabschluss zu Ende Januar) profitieren?
Oder nur Leute die zum Jahresanfang zu viel Geld rum liegen haben?
@Renegade
Übernahme in den nächsten 2 Jahren. Denke eher (und hoffe auch) das es in einem halben Jahr erledigt ist.
Der Biosensor ist in Massenproduktion und das Gerät selber nur noch ein Klacks.
Der letzte klinische Test und dann die Zulassung halte ich persönlich auch für abgehakt.
Und bevor sich ChroMedX am Markt anfängt zu etablieren und Gewinne reinkommen, kommt ein großer und schnappt sich hoffentlich das Paket.
Aber wenn man den Unternehmenswert in diesen 2 Jahren vorhat zu steigern, warum sollte dann ein Big Player solange warten und dann wesentlich mehr Geld zahlen?
In einem halben Jahr sind Tests und Zulassung durch und es kann in den Markt gegangen werden. Also ist die Firma noch recht "billig" zu haben. Und das mit einem fertigen Produkt.
Warte ich noch 1 1/2 Jahre ab werde ich sicherlich viel mehr bezahlen müssen.
Ich hoffe natürlich darauf, dass ein Big Player sich die Firma vorher schnappt und wir Aktionäre gut dabei weg kommen.
Sollte es eine Long Position werden, muss ich das aushalten und Jahre warten bis die Aktie auf ein Verkaufsnieveau gestiegen ist, wo man verkaufen kann.
Das einzige was dazu gekommen ist, ist eine Begrenzung der Provision auf maximal 11%
Dies sehe ich positiv, denn egal wie hoch eine Übernahme wird. es bleibt bei 11%
Nun heißt es wohl abwarten wann der klinische Test durchgeführt bzw. abgeschlossen wird und wann danach die Einreichung bei der Behörde folgt.
Wie seht ihr die News? Alles soweit erwartet oder zu wenig? Lese ich vielleicht selbst zu wenig heraus?
Grüße AKWG
hat ja schon ein dicken deal mit epoc damals gemacht. Sind wir mehr Wert? Vorzeichen stehen gut. Jetzt könnte quasi theopraktisch jeden Tag was kommen. Ich wüsste gerne wie das mit dem QM und Fda Zulassung steht..
January 03, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company.
In August 2017 ChroMedX retained the consulting company for an evaluation of the HemoPalm Analyzer’s product viability, value offering, and market potential. Following an initial 90-day due diligence term ChroMedX accepted a proposal from DxEx and entered into a binding Letter-of-Intent stipulating a 60-day period for the companies to form and execute a definitive agreement. The definitive agreement has now been finalized and signed by both parties.
The DxEconomix transaction team is led by CEO Dr. Richard Janeczko and Director Dr. Thomas Schlumpberger.
“With this agreement the Dx Economix team begins in earnest the rapid progression of ChroMedX through the critical stages in building a high value transaction outcome for the shareholders. We see HemoPalm as a game-changer in point-of-care diagnostics for management of critically ill patients and we expect strong positive responses from the strategic market players. There’s a lot of work to do to put it together but everyone at DxEx is already working hard with the growing team at ChroMedX and we are confident we will be successful.” said Dr. Richard Janeczko
Under this agreement DxEconomix will lead initiatives to increase the Company’s profile, maximize the HemoPalm’s value proposition and initiate engagement with important strategic industry players.
“Richard, Thomas and their team bring an almost unparalleled expertise to the Company from the global diagnostics and point-of-care blood gas field.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “With the conclusion of this agreement, ChroMedX is poised to benefit greatly from the past experience of Dx, especially the knowledge gained by Thomas as a key member of the team responsible for the high-value transaction of Epocal.”
The contract is a success fee agreement with an escalating fee schedule based on potential CAD$ transaction totals. ChroMedX agrees to pay DxEx a success fee on completion of a business transaction, being a sale of the Company, merger or plan of arrangement involving the disposition of ChroMedX or any similar disposition transaction.
The agreement stipulates an initial 24 month term where transactions for up to CAD$250MM would provide the consultant with a fee of equal to or less than 10.5% of the transaction total. Transactions above this threshold would be capped at 11%.
About Dr. Richard Janeczko
Dr. Janeczko is a 25-year veteran of the in-vitro diagnostics industry, specializing in the marketing and management of molecular assays, proteomics, companion diagnostics, and personalized medicine. He has led multiple diagnostic marketing projects from design and development through regulatory approval and market launch. He is a strong advocate of health economics as the key driver for new technology adoption in a global healthcare reform environment. In 2013, he formed DxEconomix to provide unique IVD marketing services based on system-wide economic impact of diagnostics and value-based pricing. DxEconomix has extensive experience in health economics, clinical sciences, and health technology assessment and adoption in multiple markets including USA, Canada and Europe.
Dr. Janeczko served as VP Emerging Markets and Technology at Luminex Corporation, as EVP Business Development and CSO at Tm Bioscience Inc., and as CEO of General Synthesis and Diagnostics. He played a lead in raising capital for Tm Bioscience and eventual sale of the company to Luminex Corp. (Austin, Texas). He holds a PhD in Biochemistry from the University of Alberta, a BSc in Microbiology from Strathclyde University, and is a member of several professional organizations and institutions.
About Dr. Thomas Schlumpberger
Thomas Schlumpberger received his PhD in Molecular and Cell Biology with distinction from the University of California at Berkeley in 1999. After receiving his PhD, Dr. Schlumpberger worked as a consultant for McKinsey & Company in Korea and the US for 3 years. From 2003-5 Dr. Schlumpberger built the clinical molecular diagnostics at Affymetrix. In late 2005, he joined Life Technologies as the strategic counsel to the president and BU heads. Dr. Schlumpberger joined Epocal in 2007 and played a leading role in the launch and initial commercialization of the epoc system for world-wide, ex-USA markets before leading the team which positioned Epocal for acquisition by Alere. Dr. Schlumpberger concluded the sale of Epocal to Alere for $US 295 million in 2010. Subsequently he served as Chief Commercial Officer at InVitae, San Francisco where he was responsible for product launch and commercialization at Invitae Inc (San Francisco, CA) a genetic testing laboratory in San Francisco. He joined Dx Economix Inc. in 2013 as a board member where he oversaw numerous projects involving value-based marketing for multiple IVD products. In 2015, Dr. Schlumpberger joined Singulex Inc. (Alameda, CA), where currently he heads corporate development, new business building and alliance management. Most recently, he secured a $50 million strategic investment from Grifols SA (Barcelona, Spain).
About DxEconomix Inc.
DxEconomix Inc. is a marketing group providing assistance to medical device companies including IVD businesses. Using health economic impact analyses DxEx defines the positioning landscape, value proposition and value-based pricing options for client services and products. In this way DxEx helps our clients understand the real value they bring to healthcare systems, how to use this to obtain better pricing and better understand returns on their investments. The Company also works with clients to optimize design inputs for new tests or adapt existing diagnostics. DxEconomix develops modes of application and source key technologies to create products to overcomes market access obstacles. The Company also helps broker commercial relationships between clients and key stakeholders providing new market channels to IVD companies and creating value for healthcare systems.
Website
Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
https://www.wallstreet-online.de/nachricht/...basierten-transaktionen
January 03, 2018 ChroMedX Corp. (the Company) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company.
In August 2017 ChroMedX retained the consulting company for an evaluation of the HemoPalm Analyzers product viability, value offering, and market potential. Following an initial 90-day due diligence term ChroMedX accepted a proposal from DxEx and entered into a binding Letter-of-Intent stipulating a 60-day period for the companies to form and execute a definitive agreement. The definitive agreement has now been finalized and signed by both parties.
The DxEconomix transaction team is led by CEO Dr. Richard Janeczko and Director Dr. Thomas Schlumpberger.
With this agreement the Dx Economix team begins in earnest the rapid progression of ChroMedX through the critical stages in building a high value transaction outcome for the shareholders. We see HemoPalm as a game-changer in point-of-care diagnostics for management of critically ill patients and we expect strong positive responses from the strategic market players. Theres a lot of work to do to put it together but everyone at DxEx is already working hard with the growing team at ChroMedX and we are confident we will be successful. said Dr. Richard Janeczko
Under this agreement DxEconomix will lead initiatives to increase the Companys profile, maximize the HemoPalms value proposition and initiate engagement with important strategic industry players...........
Link: https://www.chromedx.com/...e-agreement-with-dxeconomix-to-lead-value
Optionen
| Boardmail an "Kampfschwein300" |
Wertpapier: Scryb Inc |
Da der Vertrag rund 3 Wochen vor Fristsetzung unter Dach und Fach ist, kommen bei mir Gedanken auf, dass man intern schon weiter ist.
DxEx scharrt vielleicht schon mit den Hufen um das Potenzial von ChroMedX auszuschöpfen.
Eventuell sind ein oder auch mehrere potenzielle/n Partner schon in Anfangsgesprächen und man möchte bei DxEx nicht erst in 3 Wochen den Vertrag haben um den Gewinn für einen selber nicht zu verringern.
Vielleicht ist man auch nur bei den Bedingungen des Vertrages schon im voraus so einig gewesen, dass die Unterschrift nur noch Formsache war.
Wie schon gesagt, ich hoffe auf eine Übernahme und guten Gewinn dabei für uns Aktionäre.
Optionen
| Boardmail an "Kampfschwein300" |
Wertpapier: Scryb Inc |
Optionen
| Boardmail an "DerInvestor2016" |
Wertpapier: Scryb Inc |
Das kannst du dann annehmen oder ablehnen.
Ich glaube 75% aller Aktieninhaber müssen dann zustimmen um das Angebot wirksam werden zu lassen.
Ist es das werden alle ihre Aktien zu den Konditionen abgeben die Vertraglich festgehalten wurden.
Das sind jetzt Infos ohne mal nachgeforscht zu haben, rein aus meinem halbwissen heraus.
Vielleicht hat ja ein anderer schon Erfahrungen damit gemacht.